[Pharmacokinetics of two beta blocking drugs: detection of a pharmacogenetic abnormality]
- PMID: 12563
[Pharmacokinetics of two beta blocking drugs: detection of a pharmacogenetic abnormality]
Abstract
10 healthy male volunteers received orally either 100 mg tolamolol or 20 mg bufuralol. These experiments were repeated by intravenous administration of 10 and 5 mg respectively of these two drugs. Plasma levels of the parent drugs and their main metabolite were measured. In one subject, the apparent half-life of elimination was increased from 2.5 h (normal subjects) to 5 h for both drugs. This prolongation of the half-life is associated with low plasma levels of the metabolites, a peculiarity which can be explanined by a decreased rate of metabolism for these two drugs. This anomaly may explain the marked orthostatic hypotension observed only in this subject. The likelihood of a pharmacogenetic defect is discussed.
Similar articles
-
[Role of metabolites in the relationship between pharmacokinetics and the effect of beta blockers. Studies on tolamolol and bufuralol].Schweiz Med Wochenschr. 1978 May 20;108(20):756-64. Schweiz Med Wochenschr. 1978. PMID: 26114 French.
-
[Effects of tolamolol and bufuralol on the arterial blood pressure and plasma renin activity. Contribution to the study of beta-blocking agents action mechanisms (author's transl)].Schweiz Rundsch Med Prax. 1978 Jan 3;67(1):27-35. Schweiz Rundsch Med Prax. 1978. PMID: 23523 French. No abstract available.
-
Proceedings: Preliminary studies of Ro 3-3528, a beta-adrenoceptor-blocking agent, in man.Br J Pharmacol. 1972 Feb;44(2):377P-378P. Br J Pharmacol. 1972. PMID: 4148922 Free PMC article. Clinical Trial. No abstract available.
-
Consequences of renal insufficiency on the hepatic clearance of some drugs.Int J Clin Pharmacol Res. 1983;3(6):459-74. Int J Clin Pharmacol Res. 1983. PMID: 6147317 Review.
-
Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 1. Pharmacodynamic and pharmacokinetic properties.Am Heart J. 1979 May;97(5):663-70. doi: 10.1016/0002-8703(79)90195-9. Am Heart J. 1979. PMID: 34989 Review. No abstract available.
Cited by
-
The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.Clin Pharmacokinet. 1986 Jan-Feb;11(1):1-17. doi: 10.2165/00003088-198611010-00001. Clin Pharmacokinet. 1986. PMID: 2868819 Review.
-
Influence of renal failure on the hepatic clearance of bufuralol in man.J Pharmacokinet Biopharm. 1980 Oct;8(5):421-38. doi: 10.1007/BF01059544. J Pharmacokinet Biopharm. 1980. PMID: 6114166
-
Personalized medicine - where do we stand? Pouring some water into wine: a realistic perspective.Croat Med J. 2012 Aug;53(4):314-20. doi: 10.3325/cmj.2012.53.314. Croat Med J. 2012. PMID: 22911523 Free PMC article.
-
Oxidation phenotype and the metabolism and action of beta-blockers.Klin Wochenschr. 1985 Apr 1;63(7):285-92. doi: 10.1007/BF01731972. Klin Wochenschr. 1985. PMID: 2860267 Review.
-
Pharmacodynamic and pharmacokinetic studies on bufuralol in man.Br J Clin Pharmacol. 1986 Nov;22(5):527-34. doi: 10.1111/j.1365-2125.1986.tb02931.x. Br J Clin Pharmacol. 1986. PMID: 2878678 Free PMC article. Clinical Trial.